Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Phathom Pharmaceuticals (PHAT)
NASDAQ:PHAT
RESEARCH TOOLSreports
Holding PHAT?
Track your performance easily
Phathom Pharmaceuticals (PHAT) Ownership Overview
18.30% Insiders
9.38% Mutual Funds
11.06% Other Institutional Investors
8.37% ETFs
52.90% Public Companies and
Individual Investors
The ownership structure of Phathom Pharmaceuticals (PHAT) stock is a mix of institutional, retail, and individual investors. Approximately 28.80% of the company’s stock is owned by Institutional Investors, 18.30% is owned by Insiders, and 52.90% is owned by Public Companies and Individual Investors.
Recent Insider Trading Activity
Date | Name | Activity | Value |
|---|---|---|---|
| Apr 10, 2024 | Molly Henderson Cfo And Cbo | xxxxxxxxxxxxx | $38129 |
| Jan 25, 2024 | Takeda Pharmaceutical Co Ltd >10% Owner | xxxxxxxxxxxxx | $29999994 |
| Nov 21, 2023 | Molly Henderson Cfo And Cbo | xxxxxxxxxxxxx | $15399 |
| Nov 08, 2023 | Asit Parikh Director | xxxxxxxxxxxxx | $58580 |
Recent Hedge Fund Trading Activity
Date | Firm | Activity | Value |
|---|---|---|---|
| Jun 30, 2024 | xxxxxxxxxxxxx | $87580 | |
| Jun 30, 2024 | xxxxxxxxxxxxx | $2317500 | |
| Jun 30, 2024 | xxxxxxxxxxxxx | $8095697 | |
| Jun 30, 2024 | xxxxxxxxxxxxx | $15164267 |
Top Shareholders
Holder | # of Shares | Type | % Holding | Value |
|---|---|---|---|---|
| 5,863,424 | Insider | 8.59% | 94,107,955 | |
| 3,755,583 | Insider | 5.50% | 60,277,107 | |
| 2,557,001 | Institution | 3.74% | 41,039,866 | |
| 1,873,264 | Institution | 2.74% | 30,065,887 | |
| 1,845,423 | Institution | 2.70% | 29,619,039 | |
| 1,490,560 | Institution | 2.18% | 23,923,488 | |
| 1,472,259 | Institution | 2.16% | 23,629,757 | |
| 1,231,255 | Insider | 1.80% | 19,761,643 | |
| 1,029,699 | Insider | 1.51% | 16,526,669 | |
| 785,990 | Institution | 1.15% | 12,615,140 |
Top Mutual Fund Holders
Holder | # of Shares | Type | % Holding | Value |
|---|---|---|---|---|
| 1,845,423 | Institution | 2.70% | 29,619,039 | |
| 1,490,560 | Institution | 2.18% | 23,923,488 | |
| 746,710 | Institution | 1.09% | 11,984,696 | |
| 464,839 | Institution | 0.68% | 7,460,666 | |
| 387,408 | Institution | 0.57% | 6,217,898 | |
| 357,771 | Institution | 0.52% | 5,742,225 | |
| 249,398 | Institution | 0.37% | 4,002,838 | |
| 155,465 | Institution | 0.23% | 2,495,213 | |
| 146,581 | Institution | 0.21% | 2,352,625 | |
| 102,229 | Institution | 0.15% | 1,640,775 |
Top ETF Holders
Holder | # of Shares | Type | % Holding | Value |
|---|---|---|---|---|
| 1,646,342 | Institution | 2.41% | 29,765,863 | |
| 882,078 | Institution | 1.29% | 14,157,352 | |
| 555,813 | Institution | 0.81% | 10,049,099 | |
| 521,935 | Institution | 0.76% | 8,377,057 | |
| 250,073 | Institution | 0.37% | 4,013,672 | |
| 229,600 | Institution | 0.34% | 3,685,080 | |
| 199,961 | Institution | 0.29% | 3,209,374 | |
| 156,846 | Institution | 0.23% | 2,835,776 | |
| 173,404 | Institution | 0.25% | 2,810,879 | |
| 125,182 | Institution | 0.18% | 2,263,291 |
FAQ
Who Owns Phathom Pharmaceuticals (PHAT)?
According to the latest TipRanks data, approximately 11.06% of the company's stock is held by institutional investors, 18.30% is held by insiders, and 52.90% is held by retail investors.
What percentage of Phathom Pharmaceuticals (PHAT) stock is held by institutional investors?
According to the latest TipRanks data, approximately 11.06% of Phathom Pharmaceuticals (PHAT) stock is held by institutional investors.
What percentage of Phathom Pharmaceuticals (PHAT) stock is held by retail investors?
According to the latest TipRanks data, approximately 52.90% of Phathom Pharmaceuticals (PHAT) stock is held by retail investors.
Who owns the most shares of Phathom Pharmaceuticals (PHAT)?
James Topper owns the most shares of Phathom Pharmaceuticals (PHAT).
What is the significance of the ownership structure for a publicly traded company?
The ownership structure can impact the company's decision making, as large institutional investors may exert influence on the company's management and can also affect the company's stock price with their buying and selling patterns.